Tempest Therapeutics (TPST) Reports Mixed Q1 2026 — Revenue Beats but EPS Misses - {璐㈡姤鍓爣棰榼

Management Commentary

During the Q1 2026 earnings call, Tempest Therapeutics management emphasized progress in advancing its clinical pipeline despite the absence of revenue and a GAAP net loss of $2.53 per share. The team highlighted the ongoing development of their lead candidate, TPST-1120, in a randomized Phase 2 trial for first-line hepatocellular carcinoma, noting that enrollment continues to pace in line with internal timelines. Management pointed to encouraging signals from early data readouts, though they underscored that the results remain preliminary and require further maturation. Operational highlights included the initiation of new investigator-sponsored trials exploring TPST-1120 in combination with checkpoint inhibitors for additional solid tumor indications. The company also reported maintaining a disciplined cash management strategy, with cash runway extending into mid-2027 based on current operating plans. On the call, management reiterated a focus on generating clinically meaningful data and advancing toward potential registrational discussions with regulators, while acknowledging the challenges of operating without commercial revenue. They expressed cautious optimism about the upcoming data milestones expected later this year and emphasized the importance of maintaining a lean cost structure to support extended operations. The commentary struck a tone of measured confidence, with no forward-looking guidance beyond previously stated timelines. Tempest Therapeutics (TPST) Reports Mixed Q1 2026 — Revenue Beats but EPS Misses{闅忔満鎻忚堪}{闅忔満鎻忚堪}Tempest Therapeutics (TPST) Reports Mixed Q1 2026 — Revenue Beats but EPS Misses{闅忔満鎻忚堪}

Forward Guidance

During the recent Q1 2026 earnings call, Tempest Therapeutics management provided an update on its clinical pipeline and near-term priorities. The company expects to report initial data from its ongoing Phase 1/2 study of TPST-1495, a dual EP2/EP4 prostaglandin receptor antagonist, in combination with pembrolizumab during the second half of 2026. Additionally, management anticipates advancing its investigational candidate TPST-8841, an EGFR inhibitor, into a Phase 2 trial in selected biomarker-defined non-small cell lung cancer patients, with enrollment potentially beginning in the coming quarters. On the financial side, Tempest stated that its current cash, cash equivalents, and marketable securities are expected to fund planned operations into the second quarter of 2027, providing a runway through key data readouts. The company emphasized a disciplined approach to capital allocation and noted that it may seek additional financing opportunities to extend its cash runway and support potential development of its assets. While Tempest did not issue specific revenue or earnings guidance for the remainder of fiscal 2026, management indicated that achieving clinical milestones and demonstrating proof-of-concept data remain the primary near-term objectives. The outlook is subject to risks inherent in early-stage drug development, including patient enrollment rates, trial results, and regulatory feedback. Tempest Therapeutics (TPST) Reports Mixed Q1 2026 — Revenue Beats but EPS Misses{闅忔満鎻忚堪}{闅忔満鎻忚堪}Tempest Therapeutics (TPST) Reports Mixed Q1 2026 — Revenue Beats but EPS Misses{闅忔満鎻忚堪}

Market Reaction

Tempest Therapeutics (TPST) shares experienced notable volatility in the wake of the company’s recently released Q1 2026 results. The reported earnings per share of -$2.53, coupled with the absence of recognized revenue—consistent with its clinical-stage profile—prompted a mixed initial response from the market. In the first hours following the announcement, the stock declined, likely reflecting investor disappointment over the wider-than-expected loss and the lack of near-term revenue catalysts. However, the sell-off moderated as some analysts pointed to the company’s pipeline progress and cash runway as potential stabilizing factors. Analyst commentary has been cautious but not uniformly bearish. While several note that TPST remains a high-risk speculative name, they emphasize that the Q1 figures do not alter the fundamental thesis, which hinges on upcoming clinical data readouts rather than near-term profitability. Trading volume was elevated during the session, suggesting active repositioning by institutional and retail participants. The stock remains sensitive to sentiment around biotech small-caps, and any further movement may depend on news flow from ongoing trials. Overall, the market reaction underscores the binary nature of TPST’s risk-reward profile at this stage. Tempest Therapeutics (TPST) Reports Mixed Q1 2026 — Revenue Beats but EPS Misses{闅忔満鎻忚堪}{闅忔満鎻忚堪}Tempest Therapeutics (TPST) Reports Mixed Q1 2026 — Revenue Beats but EPS Misses{闅忔満鎻忚堪}